Latest News

China Medical System: Approval of Drug Clinical Trials for Additional Chronic Obstructive Pulmonary Disease Indication of Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection
2025-09-30

China Medical System: Approval of Drug Clinical Trials for Additional Chronic Obstructive Pulmonary Disease Indication of Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection

China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”), for which the Group holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights, has obtained the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 29 September 2025. The NMPA has agreed to conduct the clinical trial of MG-K10 for the treatment of Chronic Obstructive Pulmonary Disease (COPD).   About MG-K10 MG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13, for the treatment of type 2 inflammatory diseases. Currently marketed anti-IL-4Rα drugs require biweekly dosing, while MG-K10 has a longer half-life, enabling a four-week dosing frequency. It is expected to become the world’s first long-acting anti-IL-4Rα monoclonal antibody to be […]

Learn More
China Medical System: Approval of Phase III Drug Clinical Trials for  Additional Chronic Spontaneous Urticaria Indication of  Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection
2025-09-28

China Medical System: Approval of Phase III Drug Clinical Trials for Additional Chronic Spontaneous Urticaria Indication of Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection

China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Group on 22 April 2025 for details) together with its subsidiaries holding the co-development rights (except for atopic dermatitis (AD)) and the exclusive commercialization rights of Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”) received the drug clinical trial approval notice issued by National Medical Products Administration (“NMPA”) on 28 September 2025. The NMPA has agreed to conduct a Phase III clinical trial of MG-K10 for chronic spontaneous urticaria (CSU).   About MG-K10 MG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13, for the treatment of type 2 inflammatory […]

Learn More
15 Years of Dedication, Pioneering the Future with Innovation丨China Medical System’s 15th Anniversary of Listing on the Hong Kong Stock Exchange
2025-09-28

15 Years of Dedication, Pioneering the Future with Innovation丨China Medical System’s 15th Anniversary of Listing on the Hong Kong Stock Exchange

Learn More

The news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.

All News